← Leaderboards
Kenneth Olivier
Boston Immune Technologies And Therapeutics, Inc.
$3,621,523
Attributed
$3,621,523
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,621,523 · 2
By mechanism
R44$3,621,523 · 2
Top collaborators
No co-investigators on record.
Most similar at Boston Immune Technologies And Therapeutics, Inc.
Same institution · by research overlap
- David G Brooks$3,974,764
Others in their field
Other Emerging Leaders on “Investigational Drugs”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,497,655
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Investigational DrugsIn VivoFundingInternationalIn Vitro ActivityIn VitroDesignFrequenciesCyclic GmpInterestInvestigational New Drug ApplicationDimerDrug KineticsBenchmarkingBindingAntibodiesCellsFormulationClinical TrialsBostonFutureImmuneDoseLarge Scale Production
Grant awards (5)
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.$926,858
R44 · FY2025 · AI · contact PI
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$776,973
R44 · FY2024 · CA · contact PI
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$1,221,684
R44 · FY2023 · CA · contact PI
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.$298,049
R44 · FY2023 · AI · contact PI
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$397,959
R44 · FY2021 · CA · contact PI